CDEK
← All drugs Report issue

rimonabant

Small moleculeexperimental

Rimonabant (also known as SR141716; trade names Acomplia, Zimulti) is an anorectic antiobesity drug approved in Europe in 2006 but was withdrawn worldwide in 2008 due to serious psychiatric side effects; it was never approved in the United States. Rimonabant is an inverse agonist for the cannabinoid receptor CB1 and was first-in-class for clinical development. — Wikipedia

Clinical trial activity

46 trials · 24 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
41
Phase 3
35
Phase 4
2

Earliest trial started Aug 1, 2001 (NCT00029861)

Timeline

2000s

  1. Jan 1, 2001

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2003

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2006

    Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

  • Cannabinoid CB1 receptorANTAGONIST

    CNR1 antagonist

    Rimonabant, a selective cannabinoid CB1 receptor antagonist, given systemically reduces the increase of the concentration of dopamine in the dialysate from the shell of the nucleus accumbens, which occurs when rats are exposed to novel high palatable foods.

Chemistry & pharmacology

Loading structure…

SMILES

Cc1c(C(=O)NN2CCCCC2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Cl)cc1
Mol. weight
463.8 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Oral

Oral

Yes

Parenteral

No

Topical

No

Sources

Also known as

  • acomplia
  • acomplia
  • acomplia
  • acomplia
  • n-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1h-pyrazole-3-carboxamide hydrochloride
  • rimonabant
  • rimonabant
  • rimonabant
  • rimonabant
  • rimonabant
  • rimonabant
  • rimonabant
  • rimonabant
  • rimonabant
  • rimonabant
  • sr-14171
  • sr-14171
  • sr141716
  • sr141716
  • sr141716
  • sr141716
  • sr 141716
  • sr-141716
  • sr-141716
  • sr141716a
  • sr141716a
  • sr141716a
  • sr141716a
  • sr141716a
  • sr141716a
  • sr 141716a
  • sr-141716a
  • sr-141716a
  • sr-141716a
  • zimulti

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05622994Phase 2Nov 30, 2022Hospital Nacional de Paraplejicos
NCT05398913Phase 1/Phase 2 (Phase 2)May 12, 2021Hospital Nacional de Paraplejicos
NCT00750347Phase 1Sep 1, 2008University Clermont Auvergne
NCT00754689Phase 3Sep 1, 2008Sanofi
NCT00690456Phase 3May 1, 2008Sanofi
NCT00656487Phase 2Apr 30, 2008National Institute on Drug Abuse (NIDA), Scripps
NCT00734123Phase 4Apr 1, 2008Hospital Universitario Arnau de Vilanova de Lleida, Pfizer
NCT00678483Phase 3Apr 1, 2008Sanofi
NCT00577148Phase 3Feb 1, 2008Sanofi
NCT00576667Phase 3Jan 1, 2008Sanofi
NCT00547118Phase 2Nov 1, 2007National Institute on Drug Abuse (NIDA), University of Maryland
NCT00546325Phase 3Oct 1, 2007Sanofi
NCT00603109Phase 3Aug 1, 2007Cornell University, National Institutes of Health (NIH), Prader Willi Syndrome Association, Winthrop University
NCT00584389Phase 4Jul 1, 2007European Foundation for the Study of Diabetes, National Health Service, United Kingdom, University of London
NCT00478972Phase 3Apr 1, 2007Sanofi
NCT00478595Phase 3Apr 1, 2007Sanofi
NCT00458081Phase 3Mar 1, 2007Sanofi
NCT00449605Phase 3Mar 1, 2007Sanofi
NCT00434096Phase 3Feb 1, 2007Sanofi
NCT00412698Phase 3Dec 1, 2006Sanofi
Showing 20 of 46 trials
Page 1 / 3

Organizations

Research & Development (24)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
SanofiFor profit353522001
National Institute on Drug Abuse (NIDA)Government3122006
Hospital Nacional de ParaplejicosAcademic/Hospital2212021
ScrippsAcademic/Hospital2122005
Aristotle University of ThessalonikiAcademic/Hospital1112005
Cornell UniversityAcademic/Hospital1112007
European Foundation for the Study of DiabetesAcademic/Hospital1012007
Hospital Universitario Arnau de Vilanova de LleidaAcademic/Hospital1112008
Mayo ClinicAcademic/Hospital1012002
National Health Service, United KingdomGovernment1012007
National Institute on Alcohol Abuse and Alcoholism (NIAAA)Government1112003
National Institutes of Health (NIH)Government1012007
PfizerFor profit1012008
Prader Willi Syndrome AssociationAcademic/Hospital1012007
Sanofi-SynthelaboFor profit1012003
Toho UniversityAcademic/Hospital1012004
University Clermont AuvergneAcademic/Hospital1112008
University of AmsterdamAcademic/Hospital1012005
University of AthensAcademic/Hospital1012005
University of LeedsAcademic/Hospital1012004
24 organizations
Page 1 / 2